LOGIN  |  REGISTER
Recursion
Amneal Pharmaceuticals

Nyxoah: Information on the Total Number of Voting Rights and Shares

August 30, 2023 | Last Trade: US$6.43 0.08 1.26

Mont-Saint-Guibert (Belgium), August 30, 2023, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  • Share capital: EUR 4,925,869.05
  • Total number of securities carrying voting rights: 28,673,985 (all ordinary shares)
  • Total number of voting rights (= denominator): 28,673,985 (all relating to ordinary shares)
  • Number of rights to subscribe to securities carrying voting rights not yet issued:
  • 100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);  
  • 410,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 410,500 securities carrying voting rights (all ordinary shares); and
  • 1,265,500 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,265,500 securities carrying voting rights (all ordinary shares); and
  • 700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).

Contacts:

Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page